開拓藥業(09939.HK)新藥研究申請獲國家藥監局CDE批准
開拓藥業-B(09939.HK)公布,GT20029用於雄激素性脫髮及痤瘡適應症的新藥研究「IND」申請臨床試驗已獲中國國家藥監局藥品審評中心「CDE」批准。集團正準備臨床試驗,預期將今年第三季開始招募受試者。
GT20029是一種使用集團自主開發的靶向蛋白降解嵌合體「PROTAC」平台開發的外用雄激素受體「AR」化合物,是全球首個進入臨床階段的外用PROTAC化合物。集團亦正準備GT20029於美國的IND申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.